K. H. Vincent Lau

ORCID: 0000-0003-1416-5589
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Multiple Myeloma Research and Treatments
  • Amyloidosis: Diagnosis, Treatment, Outcomes
  • Protein Degradation and Inhibitors
  • Telemedicine and Telehealth Implementation
  • COVID-19 and healthcare impacts
  • Innovations in Medical Education
  • Healthcare Systems and Technology
  • Clinical Reasoning and Diagnostic Skills
  • Hereditary Neurological Disorders
  • Peripheral Neuropathies and Disorders
  • Long-Term Effects of COVID-19
  • Cancer Treatment and Pharmacology
  • Online and Blended Learning
  • Cellular transport and secretion
  • Myasthenia Gravis and Thymoma
  • Innovations in Educational Methods
  • Head and Neck Cancer Studies
  • COVID-19 Clinical Research Studies
  • Liver physiology and pathology
  • Radiology practices and education
  • Chronic Disease Management Strategies
  • Protein Kinase Regulation and GTPase Signaling
  • Brain Metastases and Treatment
  • Geriatric Care and Nursing Homes
  • Social Media in Health Education

Boston University
2020-2024

SUNY Downstate Health Sciences University
2024

Maimonides Medical Center
2024

Weill Cornell Medicine
2024

Cornell University
2024

Boston Medical Center
2019-2023

Policlinico San Matteo Fondazione
2023

Istituti di Ricovero e Cura a Carattere Scientifico
2023

Amyloidosis Foundation
2022-2023

Mass General Brigham
2022

ABSTRACT Introduction : While anticancer immunotherapies have traditionally focused on activation of the immune system, there is recent interest in disinhibition natural antitumor response by targeting checkpoints such as cytotoxic T‐lymphocyte associated antigen‐4 (CTLA‐4) and programmed death‐1 (PD‐1). One humanized monoclonal antibody against PD‐1, pembrolizumab, was recently approved for treatment metastatic malignant melanoma. Methods We report exacerbation myasthenia gravis (MG) after...

10.1002/mus.25141 article EN Muscle & Nerve 2016-04-11

Background Preclinical data suggest that sunitinib enhances the efficacy of radiotherapy. We tested combination and hypofractionated image-guided radiotherapy (IGRT) in a cohort patients with historically incurable distant metastases. Methods Twenty five oligometastases, defined as 1–5 sites active disease on whole body imaging, were enrolled phase II trial from 2/08 to 9/10. The most common tumor types treated head neck, liver, lung, kidney prostate cancers. Patients recommended dose 37.5...

10.1371/journal.pone.0036979 article EN cc-by PLoS ONE 2012-06-27

Background: The video-based lecture (VBL), an important component of the flipped classroom (FC) and massive open online course (MOOC) approaches to medical education, has primarily been evaluated through direct learner feedback. Evaluation may be enhanced analytics (LA) – analysis quantitative audience usage data generated by video-sharing platforms.Methods results: We applied LA experimental series ten VBLs on electroencephalography (EEG) interpretation, uploaded YouTube in model a publicly...

10.1080/0142159x.2017.1395001 article EN Medical Teacher 2017-11-07

High-dose melphalan and stem cell transplantation (HDM/SCT) is an effective treatment for selected patients with AL amyloidosis. We report the long-term outcomes of 648 amyloidosis treated HDM/SCT over 25 years. Hematologic CR was achieved by 39% patients. The median duration hematologic 12.3 years, 45% a had no evidence recurrent plasma dyscrasia at 15 years after HDM/SCT. With follow-up interval 8 event-free survival (EFS) overall (OS) were 3.3 7.6 respectively. Patients OS 30% these...

10.1002/ajh.26641 article EN American Journal of Hematology 2022-06-22

Filanesib is a kinesin spindle protein inhibitor that has demonstrated encouraging activity in patients with recurrent/refractory multiple myeloma. Preclinical synergy bortezomib was the rationale for current phase 1 study.The study multicenter an initial dose-escalation to determine maximum tolerated dose of 2 schedules filanesib plus and without dexamethasone, followed by dose-expansion phase.With addition prophylactic filgastrim, planned attained: 1.3 mg/m2 /day 40 mg dexamethasone on...

10.1002/cncr.30174 article EN Cancer 2016-07-19

We have shown a high prevalence of liver fibrosis in elderly cadavers with diverse causes death by Sirius red stain; however, the various collagen types these samples yet to be evaluated. To further characterize histopathology fibrotic lesions livers cadavers, this study used immunohistochemistry and histochemistry identify principal collagens produced fibrosis, fibrogenic cells elastic fibers. Collagen I III immunoreactions were found colocalize fibers central veins, perisinusoidal foci,...

10.1002/ar.22504 article EN The Anatomical Record 2012-05-30

As the concept of a clinician-educator (CE) evolves and multiple competencies role become better defined, there seems to be growing need for targeted training clinicians pursuing career in medical education. This study aims describe current state CE tracks adult neurology residency programs identify barriers implementation, potential solutions, program goals outcomes.

10.1212/ne9.0000000000200142 article EN Neurology Education 2024-08-06

Abstract Objective Our aim is to explore the common challenges encountered by neurologists in telemedicine. Methods We performed a cross-sectional study via an anonymous survey neurologists’ experiences with A was sent randomly selected 200 participants from academic institutions United States. descriptive statistics, reported as percentages for each question. Results One hunderd and ten completed survey. Fifty-one percent of stated that they experienced technological issues (1%–20%)...

10.1007/s44250-024-00098-2 article EN cc-by Discover Health Systems 2024-06-03

Relapsed/refractory multiple myeloma patients treated with pomalidomide and dexamethasone have an overall response rate (ORR) of ∼30% median progression-free survival (PFS) 4–5 months. Previous studies explored addition weekly cyclophosphamide, but we hypothesized that daily dosing allows for better synergy. We report the open-label, single-center phase II study pomalidomide, cyclophosphamide (PCD). Thirty-three were evaluable efficacy underwent 28-day cycles (4 mg/day, D1-21), (50 mg...

10.1080/10428194.2020.1805111 article EN cc-by-nc-nd Leukemia & lymphoma/Leukemia and lymphoma 2020-07-28

Hereditary gelsolin (AGel) amyloidosis is a systemic disease that characterised by neurologic, ophthalmologic, dermatologic, and other organ involvements. We describe the clinical features with focus on neurological manifestations in cohort of patients AGel referred to Amyloidosis Centre United States.Fifteen were included study between 2005 2022 permission Institutional Review Board. Data collected from prospectively maintained database, electronic medical records telephone...

10.1080/13506129.2023.2204999 article EN Amyloid 2023-05-04
Coming Soon ...